Literature DB >> 20303018

Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing.

Philippa C May1, Nicola Foot, Robert Dunn, Helen Geoghegan, Michael J Neat.   

Abstract

In recent years it has become increasingly evident that MYC rearrangements are not confined to classical Burkitt lymphoma (BL), but also occur in diffuse large B-cell lymphoma (DLBCL) and in the new subtype, "B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL" (BCLU), which was recently described in the 2008 revision of the World Health Organization classification. The accurate identification of MYC rearrangements in these three subtypes of high-grade lymphoma is becoming increasingly critical both in terms of diagnosis of classical BL and in light of the prognostic implications in cases of DLBCL and BCLU. We describe three cases of high-grade lymphoma in which cryptic insertion events, resulting in clinically significant IGH-MYC rearrangements, were detectable using an IGH/MYC three-color, dual-fusion fluorescence in situ hybridization (FISH) probe set, but were not detected using break-apart MYC FISH probes, thus highlighting the limitations of using break-apart probes as a stand-alone test, particularly with the increased use of interphase FISH analysis of formalin-fixed, paraffin-embedded tissue sections in the diagnostic work-up of these patients. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20303018     DOI: 10.1016/j.cancergencyto.2009.12.010

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms.

Authors:  Rebecca L King; Ellen D McPhail; Reid G Meyer; George Vasmatzis; Kathryn Pearce; James B Smadbeck; Rhett P Ketterling; Stephanie A Smoley; Patricia T Greipp; Nicole L Hoppman; Jess F Peterson; Linda B Baughn
Journal:  Haematologica       Date:  2018-12-06       Impact factor: 9.941

2.  Comparison Between Integrated Genomic DNA/RNA Profiling and Fluorescence In Situ Hybridization in the Detection of MYC, BCL-2, and BCL-6 Gene Rearrangements in Large B-Cell Lymphomas.

Authors:  Daniel P Cassidy; Jennifer R Chapman; Rafael Lopez; Kyle White; Yao-Shan Fan; Carmen Casas; Eric A Severson; Francisco Vega
Journal:  Am J Clin Pathol       Date:  2020-02-08       Impact factor: 2.493

3.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

Authors:  John S Welch; Peter Westervelt; Li Ding; David E Larson; Jeffery M Klco; Shashikant Kulkarni; John Wallis; Ken Chen; Jacqueline E Payton; Robert S Fulton; Joelle Veizer; Heather Schmidt; Tammi L Vickery; Sharon Heath; Mark A Watson; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

4.  High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Authors:  Lauren C Chong; Susana Ben-Neriah; Graham W Slack; Ciara Freeman; Daisuke Ennishi; Anja Mottok; Brett Collinge; Pau Abrisqueta; Pedro Farinha; Merrill Boyle; Barbara Meissner; Robert Kridel; Alina S Gerrie; Diego Villa; Kerry J Savage; Laurie H Sehn; Reiner Siebert; Ryan D Morin; Randy D Gascoyne; Marco A Marra; Joseph M Connors; Andrew J Mungall; Christian Steidl; David W Scott
Journal:  Blood Adv       Date:  2018-10-23

5.  High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.

Authors:  David W Scott; Rebecca L King; Annette M Staiger; Susana Ben-Neriah; Aixiang Jiang; Heike Horn; Anja Mottok; Pedro Farinha; Graham W Slack; Daisuke Ennishi; Norbert Schmitz; Michael Pfreundschuh; Grzegorz S Nowakowski; Brad S Kahl; Joseph M Connors; Randy D Gascoyne; German Ott; William R Macon; Andreas Rosenwald
Journal:  Blood       Date:  2018-02-23       Impact factor: 25.476

6.  Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements.

Authors:  Jess F Peterson; Beth A Pitel; Stephanie A Smoley; George Vasmatzis; James B Smadbeck; Patricia T Greipp; Rhett P Ketterling; William R Macon; Linda B Baughn
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-06-03

7.  Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.

Authors:  Heyjin Kim; Hee-Jin Kim; Sun-Hee Kim
Journal:  Ann Lab Med       Date:  2020-09       Impact factor: 3.464

Review 8.  Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature.

Authors:  Renata Woroniecka; Grzegorz Rymkiewicz; Lukasz M Szafron; Katarzyna Blachnio; Laura A Szafron; Zbigniew Bystydzienski; Barbara Pienkowska-Grela; Klaudia Borkowska; Jolanta Rygier; Aleksandra Kotyl; Natalia Malawska; Katarzyna Wojtkowska; Joanna Parada; Anita Borysiuk; Victor Murcia Pienkowski; Malgorzata Rydzanicz; Beata Grygalewicz
Journal:  PLoS One       Date:  2022-02-15       Impact factor: 3.240

9.  MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma.

Authors:  Linda B Baughn; Jess F Peterson; Marie-France Gagnon; Kathryn E Pearce; Patricia T Greipp; Xinjie Xu; Nicole L Hoppman; Rhett P Ketterling; Ellen D McPhail; Rebecca L King
Journal:  Blood Cancer J       Date:  2021-11-24       Impact factor: 11.037

10.  The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.

Authors:  Neeraj Sharma; James B Smadbeck; Nadine Abdallah; Cinthya Zepeda-Mendoza; Moritz Binder; Kathryn E Pearce; Yan W Asmann; Jess F Peterson; Rhett P Ketterling; Patricia T Greipp; P Leif Bergsagel; S Vincent Rajkumar; Shaji K Kumar; Linda B Baughn
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.